Zobrazeno 1 - 10
of 17
pro vyhledávání: '"J M Sorensen"'
Publikováno v:
Leukemialymphoma. 5
Current therapies for chronic lymphocytic leukemia (CLL) have not substantially improved the survival of these patients (pts). As a result treatment has been primarily palliative. One major obstacle in designing innovative therapies has been a lack o
Autor:
W. E. Cooper, J. M. Sorensen
The scientific study of speech production has been undertaken within a variety of disciplines, including linguistics, physiology, physical acoustics, and psychology, among others. In recent years, it has become possible to combine the knowledge accum
Autor:
B Coiffier, Donald A. Vena, Luciana Annino, J M Sorensen, Joseph M. Connors, Martin S. Tallman, M J Montello, Bruce D. Cheson, Jane Barrett, Francesco Lauria, Eugenio Damasio
Publikováno v:
Journal of Clinical Oncology. 16:3007-3015
PURPOSE To provide cladribine (CdA) to physicians for the treatment of patients with previously treated or untreated hairy cell leukemia (HCL), and to determine the response rate, response duration, survival, and toxicity with this agent. PATIENTS AN
Autor:
Peter C. Adamson, Mike Montello, Frank M. Balis, Brigitte C. Widemann, Michelle O'Brien, J M Sorensen, Robert F. Murphy
Publikováno v:
Journal of Clinical Oncology. 15:2125-2134
PURPOSE Methotrexate nephrotoxicity can lead to delayed methotrexate elimination and the development of life-threatening toxicity, which may not be preventable with the standard rescue agent leucovorin. In preclinical studies, we previously demonstra
Autor:
P. T. C. Ho, James M. Pluda, M. C. Christian, J. M. Sorensen, Bruce D. Cheson, Susan G. Arbuck
Publikováno v:
Annals of Oncology. 8:S119-S128
While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the mainstay of therapy. Several new chemotherapy agents, including puri
Publikováno v:
Journal of Clinical Oncology. 12:2216-2228
PURPOSE The purine analogs, fludarabine, cladribine, and pentostatin, are active against a broad spectrum of indolent lymphoid malignancies. They also have similar toxicities, including myelosuppression, immunosuppression, and sporadic neurotoxicity.
Autor:
Barnett S. Kramer, Robert F. Murphy, J M Hamilton, Nanette McAtee, L J Goldstein, Frank M. Balis, J M Sorensen, Jean L. Grem, Seth M. Steinberg, O Sartor
Publikováno v:
Journal of Clinical Oncology. 9:1811-1820
Thirty-one assessable patients with metastatic adenocarcinoma of the gastrointestinal tract were entered onto a pilot study designed to assess the impact of recombinant interferon alpha-2a (rIFN alpha-2a) on the toxicity and pharmacokinetics of fluor
Autor:
N L Gusa, Charles L. Loprinzi, James A. Mailliard, Ann Marie Dose, Terry M. Therneau, Laurie M. Athmann, D J Mahood, J M Sorensen, D K Gainey, Michael H. Veeder
Publikováno v:
Journal of Clinical Oncology. 9:449-452
Mucositis is a significant dose-limiting toxicity associated with fluorouracil (5FU), particularly when it is combined with leucovorin. We hypothesized that oral cryotherapy would cause local vasoconstriction and would temporarily decrease blood flow
Autor:
J L, Grem, J M, Sorensen, E, Cullen, C H, Takimoto, S M, Steinberg, A P, Chen, J M, Hamilton, S G, Arbuck, N, McAtee, D, Lawrence, B, Goldspiel, P G, Johnston, C J, Allegra
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(9)
The purpose of this study was to perform a Phase I trial of raltitrexed, a selective inhibitor of thymidylate synthase, and to determine the pharmacokinetic and toxicity profiles as a function of raltitrexed dose. Fifty patients with advanced solid t
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(7)
PURPOSE To quantify the incidence and severity of tumor lysis syndrome (TLS) as a consequence of fludarabine therapy in patients with advanced chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS A retrospective review and questionnaire follow-up